| | Characteristics | Total population () | NA-naïve () | NA-experienced, viraemic () | NA-experienced, nonviraemic () |
| | Gender, male, (%) | 31 (68.9) | 11 (73.3) | 15 (75) | 5 (50) | | Age (years), means (SD) | 45.1 (11.5) | 41 (13) | 46 (10) | 48 (12) | | Age range (years), (%) | | | | | | <50 | 31 (68.9) | 13 (86.7) | 13 (65) | 5 (50) | | ≥50 | 14 (31.1) | 2 (13.3) | 7 (35) | 5 (50) | | Hypertension, (%) | 5 (11,1) | 3 (20) | 1 (5) | 1 (10) | | Diabetes, (%) | 4 (8.9) | 3 (20) | 0 (0) | 1 (10) | | Methods of HBV discovery, (%) | | | | | | Routine screening | 34 (75.6) | 10 (66.7) | 18 (90) | 6 (60) | | Etiological work-up chronic liver disease | 7 (15.6) | 3 (20) | 0 (0) | 4 (40) | | Disturbances in liver tests | 4 (8.9) | 2 (13.3) | 2 (10) | 0 (0) | | HBeAg positive | 30 (66.7) | 10 (66.7) | 17 (85) | 3 (30) | | HBeAg negative | 15 (33.3) | 5 (33.3) | 3 (15) | 7 (70) | | Fibrosis status, (%) | | | | | | F0 | 3 (6.7) | 2 (13.3) | 1 (5) | 0 (0) | | F1 | 13 (28.9) | 5 (33.3) | 6 (30) | 2 (20) | | F2 | 21 (46.7) | 5 (33.3) | 12 (60) | 4 (40) | | F3 | 1 (2.2) | 0 (0) | 1 (5) | 0 (0) | | F4 | 7 (15.6) | 3 (20) | 0 (0) | 4 (40) | | Cirrhosis, (%) | 7 (15.6) | 3 (20) | 0 (0) | 4 (40) | | Child-Pugh class (), (%) | | | | | | A | 4 (57.1) | 2 (66.7) | 0 (0) | 2 (50) | | B | 3 (42.9) | 1 (33.3) | 0 (0) | 2 (50) | | C | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | HBV-DNA (IU/mL) | | | | | | <2000 | 13 (28.9) | 0 (0) | 3 (15) | 10 (100) | | 2000–20,000 | 17 (37.8) | 7 (46.7) | 10 (50) | 0 (0) | | >20,000 | 15 (33.3) | 8 (53.3) | 7 (35) | 0 (0) | | High viral load (>1,000,000 IU/mL), (%) | 5 (11.1) | 3 (20) | 2 (10) | 0 (0) | | Undetectable viral load (<20 IU/mL), (%) | 10 (22.2) | 0 (0) | 0 (0) | 10 (100) | | Means HBV-DNA (SD) (log10 IU/mL) | 3.7 (1.8) | 4.8 (1.2) | 4.2 (1.2) | 1 (0) | | ALT (IU/L), means (SD) | 54.8 (55.2) | 76 (83) | 52 (35) | 27 (7) | | <40 | 29 (64.4) | 9 (60) | 10 (50) | 10 (100) | | 40–80 | 8 (17.8) | 2 (13.3) | 6 (30) | 0 (0) | | >80 | 8 (17.8) | 4 (26.7) | 4 (20) | 0 (0) | | Platelets (103/mm3), means (SD) | 241.6 (80.7) | 255.9 (90.7) | 266.2 (50.5) | 170.9 (80.1) | | INR, means (SD) | 1.1 (0.1) | 1.1 (0.1) | 1 (0.1) | 1.2 (0.2) | | Serum creatinine level (μmol/L), means (SD) | 69 (14.3) | 65 (14) | 69 (13) | 74 (17) | | eGFR (ml/mn/1.73 m2), means (SD) | 120.4 (20.2) | 120 (15) | 119 (21) | 110 (22) | | <60 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | 60–89 | 7 (15.6) | 0 (0) | 4 (20) | 3 (30) | | >89 | 38 (84.4) | 15 (100) | 16 (80) | 7 (70) | | Treatment-naïve (NA-naïve), (%) | 15 (33.3) | 15 (100) | - | - | | Prior NA therapy (NA-experienced), (%) | | | | | | Lamivudine | 20 (44.4) | - | 20 (100) | 0 (0) | | Full-dose tenofovir | 10 (22.2) | - | 0 (0) | 10 (100) |
|
|
